Shares of Pediatrix Medical Group, Inc. (NYSE:MD – Get Free Report) have earned an average recommendation of “Hold” from the seven brokerages that are covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $24.3333.
A number of research analysts recently weighed in on MD shares. Mizuho set a $24.00 price objective on Pediatrix Medical Group in a research report on Friday, May 8th. UBS Group increased their target price on Pediatrix Medical Group from $22.00 to $25.00 and gave the company a “neutral” rating in a research note on Tuesday, May 12th. Truist Financial upped their price target on Pediatrix Medical Group from $23.00 to $28.00 and gave the company a “hold” rating in a report on Tuesday, July 14th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $25.00 target price on shares of Pediatrix Medical Group in a research report on Wednesday. Finally, Jefferies Financial Group reissued a “buy” rating and set a $27.00 price objective on shares of Pediatrix Medical Group in a report on Monday, April 20th.
View Our Latest Analysis on Pediatrix Medical Group
Pediatrix Medical Group Stock Performance
Pediatrix Medical Group (NYSE:MD – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. Pediatrix Medical Group had a net margin of 8.96% and a return on equity of 20.05%. The company had revenue of $487.78 million during the quarter, compared to analysts’ expectations of $478.49 million. During the same period last year, the company posted $0.53 EPS. Pediatrix Medical Group’s revenue was up 4.1% on a year-over-year basis. On average, equities analysts expect that Pediatrix Medical Group will post 2.1 EPS for the current fiscal year.
Insider Activity
In related news, Director Shirley A. Weis sold 36,028 shares of Pediatrix Medical Group stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $23.75, for a total value of $855,665.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.80% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Pediatrix Medical Group
A number of large investors have recently made changes to their positions in the company. Keybank National Association OH boosted its stake in shares of Pediatrix Medical Group by 2.0% during the 1st quarter. Keybank National Association OH now owns 22,941 shares of the company’s stock worth $491,000 after purchasing an additional 458 shares during the period. Gotham Asset Management LLC lifted its stake in Pediatrix Medical Group by 0.6% in the third quarter. Gotham Asset Management LLC now owns 116,093 shares of the company’s stock worth $1,945,000 after purchasing an additional 724 shares during the last quarter. ProShare Advisors LLC boosted its position in shares of Pediatrix Medical Group by 4.6% during the fourth quarter. ProShare Advisors LLC now owns 16,816 shares of the company’s stock valued at $360,000 after buying an additional 734 shares during the period. Verition Fund Management LLC grew its stake in shares of Pediatrix Medical Group by 4.4% during the third quarter. Verition Fund Management LLC now owns 25,408 shares of the company’s stock valued at $426,000 after buying an additional 1,066 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of Pediatrix Medical Group by 77.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 2,515 shares of the company’s stock worth $54,000 after acquiring an additional 1,100 shares during the last quarter. 97.71% of the stock is currently owned by institutional investors.
About Pediatrix Medical Group
Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.
Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.
Further Reading
- Five stocks we like better than Pediatrix Medical Group
- These Outperforming Giants Are Boosting Dividends in 2026, With Yields of Up to 6.6%
- Why Analysts Are Bullish on a Stock That’s Down 20%
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
Receive News & Ratings for Pediatrix Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediatrix Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.
